quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 9, 2026

Snowflake stock gets a bold AI call from Wall Street

View original at finance.yahoo.com
Snowflake stock gets a bold AI call from Wall Street Snowflake (SNOW) wants to convince Wall Street its next act is larger than cloud data storage…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake has 779 clients with trailing 12-month product revenue greater than $1 million

    60% confidence

  • Snowflake has a Buy rating with a $300 price target, implying approximately 22.5% upside from the June 2 closing price of $244.82

    60% confidence

  • Enterprises will need Snowflake's platform before AI can go from demos to the day-to-day activities of corporations

    60% confidence

  • Snowflake aims to be seen by investors as one of the primary platforms big firms will use to organise, regulate and activate their data for AI agents

    60% confidence

  • Snowflake struck a five-year, $6 billion deal with Amazon Web Services for AI infrastructure, Graviton processors, product integrations and business AI workload migrations

    60% confidence

  • Snowflake's full-year fiscal 2027 product revenue is projected at $5.84 billion, representing 31% growth

    60% confidence

Data points we hold from this source

Snowflake Inc. · stock price244.82 USD
Snowflake Inc. · backlog9.21 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Snowflake stock gets a bold AI call from Wall Street — Source | Via News | pt.VIA.NEWS